Wiser Advisor Group LLC Sells 362 Shares of Illumina, Inc. (NASDAQ:ILMN)

Wiser Advisor Group LLC cut its holdings in Illumina, Inc. (NASDAQ:ILMN) by 40.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 538 shares of the life sciences company’s stock after selling 362 shares during the quarter. Wiser Advisor Group LLC’s holdings in Illumina were worth $70,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. O Shaughnessy Asset Management LLC raised its stake in shares of Illumina by 91.7% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 4,199 shares of the life sciences company’s stock valued at $577,000 after acquiring an additional 2,009 shares in the last quarter. SVB Wealth LLC grew its position in Illumina by 6.8% in the 1st quarter. SVB Wealth LLC now owns 3,277 shares of the life sciences company’s stock worth $450,000 after purchasing an additional 209 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Illumina by 0.4% during the 1st quarter. California State Teachers Retirement System now owns 253,629 shares of the life sciences company’s stock worth $34,828,000 after purchasing an additional 1,064 shares during the period. Motley Fool Asset Management LLC raised its position in shares of Illumina by 8.7% during the first quarter. Motley Fool Asset Management LLC now owns 4,688 shares of the life sciences company’s stock valued at $644,000 after buying an additional 374 shares during the last quarter. Finally, Tidal Investments LLC lifted its stake in shares of Illumina by 51.2% in the first quarter. Tidal Investments LLC now owns 9,901 shares of the life sciences company’s stock valued at $1,361,000 after buying an additional 3,352 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Stock Up 1.0 %

Illumina stock traded up $1.36 during mid-day trading on Monday, hitting $141.50. 131,673 shares of the company’s stock were exchanged, compared to its average volume of 2,023,531. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The company’s 50 day simple moving average is $140.61 and its 200-day simple moving average is $124.94. Illumina, Inc. has a fifty-two week low of $93.51 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter in the prior year, the company earned $0.33 earnings per share. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. As a group, analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of several recent research reports. Citigroup upped their price target on Illumina from $155.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Royal Bank of Canada upped their target price on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price target on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. UBS Group boosted their price target on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, Canaccord Genuity Group raised their price objective on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina currently has a consensus rating of “Moderate Buy” and an average target price of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.